Head & Neck Cancer Drugs Market - Forecast(2021 - 2026)

Report Code: HCR 94267 Report Format: PDF + Excel (Delivery in 48 Hrs)

Head & Neck Cancer Drugs Market Overview

Head & Neck Cancer Drugs Market size is estimated to reach $2.4 billion by 2026, growing at a CAGR of 7.3% during the forecast period 2021-2026. Malignant tumors that are formed in or around the throat, nose, tongue, salivary glands, mouth, and others relate to head and neck cancers. Targeted immune therapies are being emerged as a standard treatment choice for advanced head and neck cancers across the world and chemotherapeutic drugs are mostly being used in the combination with radiation therapy. 

Rise in the adoption of chemotherapy drugs, such as bleomycin, cetuximab, paclitaxel, capecitabine, hydroxyurea, docetaxel, 5-fluorouracil, and methotrexate, increase in the demand for head and neck cancer combination therapeutics, rise in the demand for immunotherapy drugs, and growing research and development activities to develop ideal therapeutic drugs are the factors that are set to drive the growth of the Head & Neck Cancer Drugs Market for the period.

Head & Neck Cancer Drugs Market Report Coverage

The report: Head & Neck Cancer Drugs Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Head & Neck Cancer Drugs Market.

By Drug Class: Programmed Cell Death Protein (PD) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, and Microtubule Inhibitors.
By Treatment: Chemotherapy, Immunotherapy, and Targeted Therapy.
By Distribution Channel: Hospitals, Drug Stores and Retail Pharmacies, Online Stores, and Others.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (Middle East and Africa).

Key Takeaways

  • Geographically, North America Head & Neck Cancer Drugs Market accounted for the highest revenue share in 2020 and it is poised to dominate over the period 2021-2026 owing to the growing adoption of bleomycin, cetuximab, paclitaxel, and capecitabine drugs.
  • The rise in the availability of various chemotherapy drugs, such as bleomycin, cetuximab, paclitaxel, capecitabine, hydroxyurea, and methotrexate in drug stores is driving the Drug Stores and Retail Pharmacies segment. However, the side effects associated with head and neck cancer drugs, such as anemia, vomiting, joint pain, and osteoporosis is one of the major factors that is said to reduce the growth of the Head & Neck Cancer Drugs Market.
  • Detailed analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Head & Neck Cancer Drugs Market report.

Head & Neck Cancer Drugs Market: Market Share (%) By Distribution Channel, 2020

For More Details on This Report - Request for Sample

Head & Neck Cancer Drugs Market Segment Analysis-By Treatment

The Head & Neck Cancer Drugs Market based on the Treatment can be further segmented into Chemotherapy, Immunotherapy, and Targeted Therapy. The Chemotherapy segment held the largest share in 2020 and is also estimated to be the fastest growing segment with a CAGR of 8.9% over the period 2021-2026. This growth is owing to the factors such as increase in the research and development activities by the key players to develop advanced chemotherapy drugs and the growing demand for cost-effective chemotherapy drugs. 

The adoption of chemotherapy drugs like bleomycin, cetuximab, paclitaxel, capecitabine, hydroxyurea, docetaxel, 5-fluorouracil, and methotrexate is driving the growth of the Head & Neck Cancer Drugs Market in developed countries. The Immunotherapy segment held the second largest share in 2020 owing to the factors such as rise in the adoption of immunotherapy drugs over conventional treatments and increase in the effectiveness and enhanced efficacy of immunotherapy treatment.

Head & Neck Cancer Drugs Market Segment Analysis-By Distribution Channel

The Head & Neck Cancer Drugs Market based on the Distribution Channel can be further segmented into Hospitals, Drug Stores and Retail Pharmacies, Online Stores, and Others. The Drug Stores and Retail Pharmacies segment held the largest share in 2020 owing to the factors such as increasing demand for prescription drugs and growing expansion of companies to meet the rising demand for various chemotherapy drugs. 

The rise in the availability of various chemotherapy drugs, such as bleomycin, cetuximab, paclitaxel, capecitabine, hydroxyurea, and methotrexate in drug stores is driving the growth of the Head & Neck Cancer Drugs Market. The Online Stores segment is estimated to be the fastest growing segment with a CAGR of 9.1% over the period 2021-2026. This growth is owing to the factors such as growing preference for purchasing of drugs online over traditional methods and rise in awareness about online pharmacy in developing nations.

Head & Neck Cancer Drugs Market Segment Analysis-By Geography

North America held the largest share with 33% of the overall market in 2020. The growth in this segment is owing to the factors such as growing research and development activities to develop ideal therapeutic drugs and rise in the demand for targeted immune therapies as a standard treatment choice for advanced head and neck cancers. The rise in the adoption of bleomycin, cetuximab, paclitaxel, and capecitabine drugs is driving the growth of the Head & Neck Cancer Drugs Market. 

Asia-Pacific segment is estimated to be the fastest growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as growing demand for drugs, such as hydroxyurea, docetaxel, 5-fluorouracil, and methotrexate, and increasing awareness about the importance of early screening of the disease.

Head & Neck Cancer Drugs Market Drivers

Increase in the Demand for Chemotherapy Drugs

Chemotherapy drugs, such as hydroxyurea, docetaxel, 5-fluorouracil, and methotrexate are increasingly being used across the world for the treatment of head and neck cancer owing to their ability to reduce the frequency of painful episodes. The key players are also focusing on developing advanced chemotherapy drugs owing to the rise in the prevalence of head and neck cancer, which is further propelling the growth of the Head & Neck Cancer Drugs Market.

Rise in the Adoption of Immunotherapy Drugs in Developed Nations

Immunotherapy drugs are increasingly being adopted as a standard treatment option for advanced-stage head and neck cancers in developed nations owing to their ability to boost the natural defense system to combat cancer and their efficiency in preventing cancer from spreading to other parts of the body. With the increase in the approvals of immunotherapy drugs by the Food and Drug Administration (FDA), there is also a rise in the adoption of these drugs, which is one of the major factors driving the growth of the Head & Neck Cancer Drugs Market.

Head & Neck Cancer Drugs Market Challenges

Side Effects Associated with the Head and Neck Cancer Drugs

The growing advances in cancer research across the world have permitted successful therapeutic targeting of the immune system of the patients. The advances in therapies, such as immunotherapy and targeted therapy have also aid in offering the most effective care. However, the side effects associated with head and neck cancer drugs, such as anemia, vomiting, joint pain, and osteoporosis is one of the major factors that is estimated to reduce the growth of the Head & Neck Cancer Drugs Market.

Head & Neck Cancer Drugs Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Head & Neck Cancer Drugs Market. Key companies of this market are F. Hoffmann-La Roche Ltd, Merck KGaA, Nektar Therapeutics, Immutep Limited, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Pfizer Inc, Fortress Biotech Inc, and AstraZeneca Plc among others.

Partnerships/Product Launches:

  • In March 2021, Merck KGaA has entered into a partnership with Debiopharm for the development and commercialization of xevinapant, which is an inhibitor that helps in the advanced squamous cell carcinoma of the head and neck and to explore new treatment options in areas of high unmet needs.
  • In March 2021, Immutep Limited has entered into a partnership with subsidiaries of Merck & Co Inc to develop an innovative drug for treating patients with head and neck squamous cell carcinoma (HNSCC) and to evaluate the efficacy of its lead product candidate, eftilagimod.
  • In February 2021, Nektar Therapeutics has entered into a partnership with SFJ Pharmaceuticals for supporting the development of Bempegaldesleukin drug for treating patients with head and neck cancer whose tumors express PD-L1.

Relevant Reports

Ovarian Cancer Drugs Market - Forecast (2021 - 2026)

Report Code: HCR 0350

Cancer Diagnostics Market - Forecast (2021 - 2026)

Report Code: HCR 0195

For more Lifesciences and Healthcare Market reports, please click here

1. Head & Neck Cancer Drugs Market - Overview
    1.1 Definitions and Scope
2. Head & Neck Cancer Drugs Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Drug Class
    2.3 Key trends by Distribution Channel
    2.4 Key trends by Geography
3. Head & Neck Cancer Drugs Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Head & Neck Cancer Drugs Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Head & Neck Cancer Drugs Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Head & Neck Cancer Drugs Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Head & Neck Cancer Drugs Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Head & Neck Cancer Drugs Market – By Drug Class(Market Size –$Million/$Billion)
    8.1 Programmed Cell Death Protein (PD) Inhibitors
    8.2 Epidermal Growth Factor Receptor (EGFR) Inhibitors
    8.3 Microtubule Inhibitors
9. Head & Neck Cancer Drugs Market – By Treatment(Market Size –$Million/$Billion)
    9.1 Chemotherapy
    9.2 Immunotherapy
    9.3 Targeted Therapy
10. Head & Neck Cancer Drugs Market – By Distribution Channel(Market Size –$Million/$Billion)
    10.1 Hospitals
    10.2 Drug Stores and Retail Pharmacies
    10.3 Online Stores
    10.4 Others
11. Head & Neck Cancer Drugs Market - By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Head & Neck Cancer Drugs Market - Entropy
13. Head & Neck Cancer Drugs Market – Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Head & Neck Cancer Drugs Market – Key Company List by Country Premium Premium
15. Head & Neck Cancer Drugs Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
1.3 Targeted therapy Market 2019-2024 ($M) - Global Industry Research
2.Global HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
2.1 Hospital pharmacy Market 2019-2024 ($M) - Global Industry Research
2.2 Online providers Market 2019-2024 ($M) - Global Industry Research
2.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Global Industry Research
3.Global HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 (Volume/Units)
3.3 Targeted therapy Market 2019-2024 (Volume/Units) - Global Industry Research
4.Global HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 (Volume/Units)
4.1 Hospital pharmacy Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Online providers Market 2019-2024 (Volume/Units) - Global Industry Research
4.3 Drug stores retail pharmacies Market 2019-2024 (Volume/Units) - Global Industry Research
5.North America HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
5.3 Targeted therapy Market 2019-2024 ($M) - Regional Industry Research
6.North America HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
6.1 Hospital pharmacy Market 2019-2024 ($M) - Regional Industry Research
6.2 Online providers Market 2019-2024 ($M) - Regional Industry Research
6.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Regional Industry Research
7.South America HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
7.3 Targeted therapy Market 2019-2024 ($M) - Regional Industry Research
8.South America HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
8.1 Hospital pharmacy Market 2019-2024 ($M) - Regional Industry Research
8.2 Online providers Market 2019-2024 ($M) - Regional Industry Research
8.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Regional Industry Research
9.Europe HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
9.3 Targeted therapy Market 2019-2024 ($M) - Regional Industry Research
10.Europe HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
10.1 Hospital pharmacy Market 2019-2024 ($M) - Regional Industry Research
10.2 Online providers Market 2019-2024 ($M) - Regional Industry Research
10.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Regional Industry Research
11.APAC HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
11.3 Targeted therapy Market 2019-2024 ($M) - Regional Industry Research
12.APAC HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
12.1 Hospital pharmacy Market 2019-2024 ($M) - Regional Industry Research
12.2 Online providers Market 2019-2024 ($M) - Regional Industry Research
12.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Regional Industry Research
13.MENA HEAD NECK CANCER DRUGS MARKET, BY DRUG CLASS Market 2019-2024 ($M)
13.3 Targeted therapy Market 2019-2024 ($M) - Regional Industry Research
14.MENA HEAD NECK CANCER DRUGS MARKET, BY SALES CHANNEL Market 2019-2024 ($M)
14.1 Hospital pharmacy Market 2019-2024 ($M) - Regional Industry Research
14.2 Online providers Market 2019-2024 ($M) - Regional Industry Research
14.3 Drug stores retail pharmacies Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
2.Canada Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
3.Mexico Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
4.Brazil Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
5.Argentina Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
6.Peru Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
7.Colombia Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
8.Chile Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
9.Rest of South America Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
10.UK Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
11.Germany Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
12.France Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
13.Italy Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
14.Spain Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
15.Rest of Europe Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
16.China Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
17.India Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
18.Japan Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
19.South Korea Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
20.South Africa Head & Neck Cancer Drugs Market Revenue, 2019-2024 ($M)
21.North America Head & Neck Cancer Drugs By Application
22.South America Head & Neck Cancer Drugs By Application
23.Europe Head & Neck Cancer Drugs By Application
24.APAC Head & Neck Cancer Drugs By Application
25.MENA Head & Neck Cancer Drugs By Application
26.AstraZeneca Plc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Bristol-Myers Squibb Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Eli Lilly and Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.F. Hoffmann-La Roche Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Fresenius Medical Care AG Co. KGaA, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Merck Co., Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Pfizer Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Sanofi, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Sun Pharmaceutical Industries Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Teva Pharmaceutical Industries Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)